Cargando…

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis

BACKGROUND: There is no standard second-line treatment for patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma (EP-PD-NEC). This study explored data evaluating second-line treatment in these patients. METHODS: A search of MEDLINE and EMBASE identified studies report...

Descripción completa

Detalles Bibliográficos
Autores principales:	McNamara, Mairéad G., Frizziero, Melissa, Jacobs, Timothy, Lamarca, Angela, Hubner, Richard A., Valle, Juan W., Amir, Eitan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222242/ https://www.ncbi.nlm.nih.gov/pubmed/32426044 http://dx.doi.org/10.1177/1758835920915299

Ejemplares similares

The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases
por: Kapacee, Zainul-Abedin, et al.
Publicado: (2022)

Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis
por: Frizziero, Melissa, et al.
Publicado: (2020)

Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma
por: Weaver, Jamie M. J., et al.
Publicado: (2023)

Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?
por: Frizziero, Melissa, et al.
Publicado: (2021)

Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice
por: Lamarca, Angela, et al.
Publicado: (2022)

Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice
por: Lamarca, Angela, et al.
Publicado: (2019)

The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms
por: Shah, Dinakshi, et al.
Publicado: (2021)

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma
por: McNamara, Mairéad G., et al.
Publicado: (2023)

Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Chiramel, Jaseela, et al.
Publicado: (2017)

Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres
por: Frizziero, Melissa, et al.
Publicado: (2019)

Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours
por: Chiramel, Jaseela, et al.
Publicado: (2020)

Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer
por: Pihlak, Rille, et al.
Publicado: (2023)

Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
por: Taboada, Rodrigo G, et al.
Publicado: (2022)

The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer
por: Abdul Rahman, Rozana, et al.
Publicado: (2021)

Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review
por: Shotton, Rohan, et al.
Publicado: (2021)

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
por: Lamarca, Angela, et al.
Publicado: (2018)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
por: Foy, Victoria, et al.
Publicado: (2023)

NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)
por: Craig, Zoe, et al.
Publicado: (2020)

Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review
por: Robinson, Matthew D., et al.
Publicado: (2023)

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
por: Megdanova-Chipeva, Vera G., et al.
Publicado: (2020)

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
por: Galdy, Salvatore, et al.
Publicado: (2016)

Targeted Therapies for Perihilar Cholangiocarcinoma
por: Gray, Simon, et al.
Publicado: (2022)

Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
por: Saavedra, Cristina, et al.
Publicado: (2019)

Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter
por: Exarchou, Klaire, et al.
Publicado: (2022)

Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes
por: Gray, Simon, et al.
Publicado: (2023)

Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours
por: Lewis, Alexandra R, et al.
Publicado: (2018)

Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma
por: Najran, Pavan, et al.
Publicado: (2017)

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
por: Lamarca, Angela, et al.
Publicado: (2020)

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
por: Lamarca, Angela, et al.
Publicado: (2018)

The Impact of (68)Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours
por: Cuthbertson, Daniel J., et al.
Publicado: (2021)

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
por: De Divitiis, C., et al.
Publicado: (2016)

Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice
por: Fulton, Alexander JP, et al.
Publicado: (2019)

Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol
por: Carnie, Lindsay E, et al.
Publicado: (2021)

What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature
por: McNamara, Mairéad G, et al.
Publicado: (2022)

Unusual skull base metastasis from neuroendocrine tumor: a case report
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2019)

Measuring second language performance /
por: McNamara, Timothy Francis, 1949-
Publicado: (1996)

Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary
por: Conway, Alicia-Marie, et al.
Publicado: (2022)

Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment—PanDA)
por: Carnie, Lindsay E., et al.
Publicado: (2023)

Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre
por: Clelland, Sarah, et al.
Publicado: (2023)

Germline mutations in pancreatic cancer and potential new therapeutic options
por: Pihlak, Rille, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2n30iskmrgd2qfsgeod89ig0k7